Erik Corcoran

发表

Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models.

D. Hicklin, Zhen-ping Zhu, D. Ludwig, 2009, Anticancer research.

Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice.

U. Rodeck, Yan Wu, K. Busam, 2009, Cancer Research.

CRISPR screening identifies T cell-intrinsic regulators of CD3-bispecific antibody responses

D. Ruddy, Joni W. Lam, S. Kurtulus, 2022, Frontiers in Immunology.

In vivo method for establishing synergy between antibodies to epidermal growth factor receptor and vascular endothelial growth factor receptor-2.

D. Hicklin, Zhen-ping Zhu, J. Tonra, 2009, Methods in molecular biology.

In Vitro and In Vivo Activities of SCH 56592 (Posaconazole), a New Triazole Antifungal Agent, againstAspergillus and Candida

D. Loebenberg, F. Menzel, A. Cacciapuoti, 2000, Antimicrobial Agents and Chemotherapy.

Pharmacodynamics of Levofloxacin against Pseudomonas aeruginosa with Reduced Susceptibility Due to Different Efflux Pumps: Do Elevated MICs Always Predict Reduced In Vivo Efficacy?

Angela Lee, M. Dudley, O. Lomovskaya, 2006, Antimicrobial Agents and Chemotherapy.

1-[4-(1H-Benzoimidazol-2-yl)-phenyl]-3-[4-(1H-benzoimidazol-2-yl)-phenyl]-urea derivatives as small molecule heparanase inhibitors.

P. Kussie, A. Kiselyov, A. Lahiji, 2006, Bioorganic & medicinal chemistry letters.

Synergistic Antitumor Effects of Combined Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2 Targeted Therapy

D. Hicklin, Huiling Li, Dhanvanthri S. Deevi, 2006, Clinical Cancer Research.

Targeting the platelet-derived growth factor receptor α with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: Implications as a potential therapeutic target

Peter Bohlen, Dan Lu, D. Hicklin, 2005, Molecular Cancer Therapeutics.

H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma.

M. Hao, M. Warmuth, V. Subramanian, 2017, Cancer research.

Amelioration of Alpha-1 Antitrypsin Deficiency Diseases with Genome Editing in Transgenic Mice.

Minerva E. Sanchez, Shen Shen, D. Bumcrot, 2018, Human gene therapy.

Anti-Vascular Endothelial Growth Factor Receptor-1 Antagonist Antibody as a Therapeutic Agent for Cancer

D. Hicklin, Yan Wu, D. Ludwig, 2006, Clinical Cancer Research.

Anti-Vascular Endothelial Growth Factor Receptor-1Antagonist Antibody as aTherapeutic Agent for Cancer

Yan Wu, D. Ludwig, X. Jimenez, 2006 .

Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.

H. Youssoufian, Michelle Iacolina, J. Tonra, 2011, Neoplasia.

Pharmacodynamics of RWJ-54428 against Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis in a Neutropenic Mouse Thigh Infection Model

M. Dudley, Erik Corcoran, D. Griffith, 2008, Antimicrobial Agents and Chemotherapy.

Synergistic Antitumor Effects of Combined Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2 Targeted Therapy

D. Hicklin, Huiling Li, Dhanvanthri S. Deevi, 2006, Clinical Cancer Research.

Synergistic Antitumor Effects of Combined Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2 Targeted Therapy

D. Hicklin, Huiling Li, Dhanvanthri S. Deevi, 2006, Clinical Cancer Research.

Abstract 2932: SF3B1 mutations induce aberrant mRNA splicing in cancer and confer sensitivity to spliceosome inhibition

M. Warmuth, K. Kunii, J. Feala, 2014 .

Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice.

U. Rodeck, Yan Wu, K. Busam, 2009, Cancer research.